Inclusion Criteria:

          -  Female patients, age ≦65 years

          -  Biopsy proven lymph node positive, estrogen receptor- positive primary breast cancer

          -  Must have completed a 4-cycle neo-adjuvant chemotherapy with a standard
             regimen(containing anthracycline or paclitaxel)

          -  Must have undergone surgery to remove the primary tumor by either a mastectomy or
             enlarged local excision

          -  Postoperative residual positive lymph nodes or G1/G2/G3 of Miller & Payne Grading
             System

          -  Adequate recovery from recent surgery

          -  No history of other malignancies

          -  No currently uncontrolled diseased or active infection

          -  Not pregnant or breast feeding, and on appropriate birth control if of child-bearing
             potential

          -  Adequate cardiovascular function reserve with a myocardial infarction within the past
             six month

          -  Adequate hematologic function with:

               1. Absolute neutrophil count (ANC) ≥1500/mm3

               2. Platelets ≥100,000/ mm3

               3. Hemoglobin ≥10 g/dL

          -  Adequate hepatic and renal function with:

               1. Serum bilirubin ≤1.5×UNL

               2. Alkaline phosphatase and alanine aminotransferase (ALT) ≤2.5 x ULN. (≤5 x ULN is
                  acceptable in the setting of hepatic metastasis)

               3. BUN between 1.7 and 8.3 mmol/L

               4. Cr between 40 and 110 umol/L

          -  Knowledge of the investigational nature of the study and Ability to give informed
             consent

          -  Ability and willingness to comply with study procedures.

        Exclusion Criteria:

          -  Known or suspected distant metastases

          -  Concurrent malignancy or history of other malignancy

          -  Uncontrolled diseases(e.g., heart failure, myocardial infarction within 6 months,
             arrhythmia, unstable diabetes, hypercalcemia) or active infection

          -  Geographical, social, or psychological problems that would compromise study compliance

          -  Known or suspected hypersensitivity to anthracycline or paclitaxel